Department of Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, China.
Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China.
BMJ Open Diabetes Res Care. 2020 Aug;8(1). doi: 10.1136/bmjdrc-2019-000999.
To evaluate the association of non-alcoholic fatty liver disease (NAFLD)-associated hepatic fibrosis with bone mineral density (BMD) in postmenopausal women with type 2 diabetes mellitus (T2DM) or impaired glucose regulation (IGR).
Two cohorts including 46 subjects with biopsy-proven NAFLD and 445 subjects with proton magnetic resonance spectrum-proven NAFLD were enrolled in this study. All subjects were postmenopausal women with T2DM or IGR. BMD at the lumbar spine L1-L4 and hip was measured using dual-energy X-ray absorptiometry. NAFLD fibrosis stage and NAFLD fibrosis score were used to evaluate the severity of liver fibrosis.
In subjects with liver biopsy-proven NAFLD, BMD (T-score, Z-score and BMD value) in the advanced fibrosis group were significantly lower than that in the non-advanced fibrosis group (p<0.05). Fibrosis stage was negatively associated with T-score, Z-score and BMD value after adjusting for age, body mass index (BMI) and fasting plasma glucose (FPG). Additionally, fibrosis stage was independently associated with T-score, Z-score and BMD value after adjusting for age, BMI and FPG. These results were validated in a large cohort of 445 subjects. Additionally, bone metabolism-associated factors, including calcium and phosphate, were associated with liver fibrosis, indicating that bone metabolism may play a critical role in the association between liver fibrosis and BMD. Mechanically, parathyroid hormone and biomarkers of bone formation (osteocalcin and procollagen type 1 N-terminal propeptide) and bone resorption (procollagen type I carboxy terminal peptide β special sequence) were increased in subjects with advanced liver fibrosis than in subjects without advanced liver fibrosis, indicating that liver fibrosis decreased BMD probably via increasing bone turnover.
NAFLD-associated hepatic fibrosis was negatively associated with decreased BMD in postmenopausal women with T2DM or IGR. Liver fibrosis decreased BMD probably via increasing bone turnover. Severe liver fibrosis may represent high risk for osteoporosis in postmenopausal women with T2DM or IGR.
评估非酒精性脂肪性肝病(NAFLD)相关肝纤维化与绝经后 2 型糖尿病(T2DM)或糖调节受损(IGR)女性骨密度(BMD)之间的关系。
本研究纳入了两个队列,包括 46 例经肝活检证实的 NAFLD 患者和 445 例经质子磁共振波谱证实的 NAFLD 患者。所有受试者均为绝经后 T2DM 或 IGR 女性。使用双能 X 线吸收法测量腰椎 L1-L4 和髋部的 BMD。NAFLD 纤维化分期和 NAFLD 纤维化评分用于评估肝纤维化的严重程度。
在经肝活检证实的 NAFLD 患者中,进展性纤维化组的 BMD(T 评分、Z 评分和 BMD 值)明显低于非进展性纤维化组(p<0.05)。调整年龄、体重指数(BMI)和空腹血糖(FPG)后,纤维化分期与 T 评分、Z 评分和 BMD 值呈负相关。此外,调整年龄、BMI 和 FPG 后,纤维化分期与 T 评分、Z 评分和 BMD 值独立相关。这些结果在一个包含 445 例患者的大型队列中得到了验证。此外,骨代谢相关因素,包括钙和磷酸盐,与肝纤维化相关,表明骨代谢可能在肝纤维化与 BMD 之间的关联中起关键作用。从机制上讲,与进展性肝纤维化患者相比,甲状旁腺激素和骨形成标志物(骨钙素和 I 型前胶原 N 端前肽)以及骨吸收标志物(I 型胶原羧基端肽β特殊序列)增加,表明肝纤维化通过增加骨转换导致 BMD 降低。
在绝经后 T2DM 或 IGR 女性中,NAFLD 相关肝纤维化与 BMD 降低呈负相关。肝纤维化可能通过增加骨转换导致 BMD 降低。严重的肝纤维化可能代表绝经后 T2DM 或 IGR 女性骨质疏松的高风险。